Thalidomide, A Rational Agent for Treatment of Multicentric Reticulohistiocytosis

A patient with Multifocal Reticulohistiocytosis (MRH) of skin and joints failed treatment with etanercept, methotrexate, hydroxychloroquine, prednisone, bisphosphonates and hydroxyzine. Long term treatment with thalidomide led to marked improvement in joint and cutaneous manifestations.

Detalles Bibliográficos
Autores principales: Zinn, Daniel J, Eckstein, Olive, Olsen, Mary L, Allen, Carl E, McClain, Kenneth L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289025/
https://www.ncbi.nlm.nih.gov/pubmed/32529194
http://dx.doi.org/10.35248/2684-124X.19.4.152
_version_ 1783545389341736960
author Zinn, Daniel J
Eckstein, Olive
Olsen, Mary L
Allen, Carl E
McClain, Kenneth L
author_facet Zinn, Daniel J
Eckstein, Olive
Olsen, Mary L
Allen, Carl E
McClain, Kenneth L
author_sort Zinn, Daniel J
collection PubMed
description A patient with Multifocal Reticulohistiocytosis (MRH) of skin and joints failed treatment with etanercept, methotrexate, hydroxychloroquine, prednisone, bisphosphonates and hydroxyzine. Long term treatment with thalidomide led to marked improvement in joint and cutaneous manifestations.
format Online
Article
Text
id pubmed-7289025
institution National Center for Biotechnology Information
language English
publishDate 2019
record_format MEDLINE/PubMed
spelling pubmed-72890252020-06-11 Thalidomide, A Rational Agent for Treatment of Multicentric Reticulohistiocytosis Zinn, Daniel J Eckstein, Olive Olsen, Mary L Allen, Carl E McClain, Kenneth L Dermatol Case Rep Article A patient with Multifocal Reticulohistiocytosis (MRH) of skin and joints failed treatment with etanercept, methotrexate, hydroxychloroquine, prednisone, bisphosphonates and hydroxyzine. Long term treatment with thalidomide led to marked improvement in joint and cutaneous manifestations. 2019-04-08 2019 /pmc/articles/PMC7289025/ /pubmed/32529194 http://dx.doi.org/10.35248/2684-124X.19.4.152 Text en http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Article
Zinn, Daniel J
Eckstein, Olive
Olsen, Mary L
Allen, Carl E
McClain, Kenneth L
Thalidomide, A Rational Agent for Treatment of Multicentric Reticulohistiocytosis
title Thalidomide, A Rational Agent for Treatment of Multicentric Reticulohistiocytosis
title_full Thalidomide, A Rational Agent for Treatment of Multicentric Reticulohistiocytosis
title_fullStr Thalidomide, A Rational Agent for Treatment of Multicentric Reticulohistiocytosis
title_full_unstemmed Thalidomide, A Rational Agent for Treatment of Multicentric Reticulohistiocytosis
title_short Thalidomide, A Rational Agent for Treatment of Multicentric Reticulohistiocytosis
title_sort thalidomide, a rational agent for treatment of multicentric reticulohistiocytosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289025/
https://www.ncbi.nlm.nih.gov/pubmed/32529194
http://dx.doi.org/10.35248/2684-124X.19.4.152
work_keys_str_mv AT zinndanielj thalidomidearationalagentfortreatmentofmulticentricreticulohistiocytosis
AT ecksteinolive thalidomidearationalagentfortreatmentofmulticentricreticulohistiocytosis
AT olsenmaryl thalidomidearationalagentfortreatmentofmulticentricreticulohistiocytosis
AT allencarle thalidomidearationalagentfortreatmentofmulticentricreticulohistiocytosis
AT mcclainkennethl thalidomidearationalagentfortreatmentofmulticentricreticulohistiocytosis

Ejemplares similares